|Awarded On||November 19, 2015|
|Title||Clinical Safety and Efficacy of Third party, fucosylated, cord blood derived regulatory T cells to prevent graft versus host disease|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Borje Andersson|
|Cancer Sites||Leukemia, Lymphoma, Myeloma|
Graft versus host disease (GVHD) is a life threatening complication of allogeneic stem cell transplantation with limited therapeutic options. GVHD is primarily mediated by the donor derived T-cells and the currently available treatments are directed towards suppressing T-cells. Such therapies lead to generalized immunesuppression and are associated with toxic side effects including increased rates of infection and kidney failure. Promising, novel, cell-based therapies including naturally occurring regulatory T cells (Tregs) are being explored by the transplant community to improve outcomes. However, a major limitation in its clinical application is the low cell dose of Tregs, since it only c...